News & Opinion
Top 10 Innovations
Cell & Molecular Biology
Disease & Medicine
Ecology & Environment
Genetics & Genomics
Pharma & Biotech
Image of the Day
CRISPR Patent Dispute Heard in Federal Court
Jim Daley | May 1, 2018
In an ongoing legal battle, the University of California, Berkeley has challenged the Broad Institute’s patent claims on the gene editing technology.
Severe Toxicity Reported in High-Dose AAV Gene Therapy in Animals
Jim Daley | Jan 31, 2018
Biotech stocks fell in response to the news.
Equivocal Findings of Alzheimer’s Trial Using Young Blood
Catherine Offord | Nov 6, 2017
A team of Stanford University researchers say that administering young people’s blood plasma to Alzheimer’s patients could improve cognitive function, but the results have been criticized.
Flux and Uncertainty in the CRISPR Patent Landscape
Aggie Mika | Oct 1, 2017
The battle for the control of the intellectual property surrounding CRISPR-Cas9 is as storied and nuanced as the technology itself.
Was a Drop in CRISPR Firms’ Stock Warranted?
Claire Asher | Jun 7, 2017
A study of off-target effects that sparked fear among investors of genome-editing companies receives methodological criticisms.
CAR T-Cell Trials Boast Promising Results
Diana Kwon | Jun 5, 2017
The results of two small clinical trials show that the immunotherapy is effective for multiple myeloma patients, at least in the near term.
Learning from Iceland’s Model for Genetic Research
Catherine Offord | Jun 1, 2017
The Scandinavian island’s unique combination of genetic homogeneity, genealogical tradition, and high participation in research make it a prime location for discovery and validation of drug targets.
Former Head of Genzyme Dies
Diana Kwon | May 15, 2017
Henri Termeer helped usher the biotech company into an industry behemoth.
Life Science Leaders Meet at White House
Kerry Grens | May 8, 2017
Heads of academia and industry mingled with the vice president and the secretary of Health and Human Services at a biotech summit.
Opinion: Preparing for Potential Disasters
Larissa Paschyn | Jan 25, 2017
How to increase the resiliency of biotechnology organizations in the face of emergency risks